CDKN2A and nasopharyngeal carcinoma: In addition, serum miR-663 levels in NPC patients are significantly elevated and directly target cyclin-dependent kinase inhibitor 2A (CDKN2A), thereby promoting cell cycle progression and cell proliferation 78.